28th Jan 2016 11:12
LONDON (Alliance News) - Biofrontera AG Thursday said it had seen "excellent" results from a phase III study of its Ameluz treatment for basal cell carcinoma using photodynamic therapy.
The study compared the efficacy and safety of Ameluz with Metvix, a drug that has been approved for this treatment in the European Union.
Based on the results of the study Biofrontera will apply for approval of Ameluz in the EU to the European Medicines Agency for the treatment of basal cell carcinoma. Amelux is already approved for the treatment of mild and moderate actinic keratosis, and as such, the approval for the treatment of basal cell carcinoma only requires an extension of Ameluz's current approval.
Shares in Biofrontera were down 3.3% to 132.00 pence.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
B8F.L